CELGENE
Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options. There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including mult... iple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma. In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.
CELGENE
Industry:
Biotechnology Medical
Founded:
1986-01-01
Address:
Summit, New Jersey, United States
Country:
United States
Website Url:
http://www.bms.com
Total Employee:
10001+
Status:
Active
Contact:
+1-908-673-9000
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta Font Awesome Domain Not Resolving Mobile Non Scaleable Content Nginx IPv6 Cloudflare YouTube Cloudflare Hosting Cloudflare SSL
Similar Organizations
Edison Pharmaceuticals
Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Illumina
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Tarsa Therapeutics
Tarsa Therapeutics develops an oral formulation of calcitonin for the treatment and prevention of postmenopausal osteoporosis.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2018-01-22 | Juno Therapeutics | Juno Therapeutics acquired by Celgene | 9 B USD |
| 2018-01-07 | Impact Biomedicines | Impact Biomedicines acquired by Celgene | N/A |
| 2017-01-26 | Delinia | Delinia acquired by Celgene | 300 M USD |
| 2017-01-10 | Anokion | Anokion acquired by Celgene | 45 M USD |
| 2016-12-02 | Acetylon Pharmaceuticals | Acetylon Pharmaceuticals acquired by Celgene | N/A |
| 2016-10-17 | EngMab | EngMab acquired by Celgene | 600 M USD |
| 2015-07-14 | Receptos | Receptos acquired by Celgene | 7.32 B USD |
| 2015-06-09 | Lycera | Lycera acquired by Celgene | N/A |
| 2015-04-27 | Quanticel Pharmaceuticals | Quanticel Pharmaceuticals acquired by Celgene | 485 M USD |
| 2012-01-26 | Avila Therapeutics | Avila Therapeutics acquired by Celgene | 350 M USD |
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2019-10-15 | Cyteir Therapeutics | Celgene investment in Series B - Cyteir Therapeutics | 40.2 M USD |
| 2019-09-11 | Anokion | Celgene investment in Series B - Anokion | 40 M USD |
| 2019-09-05 | immatics biotechnologies | Celgene investment in Venture Round - immatics biotechnologies | 75 M USD |
| 2019-08-21 | Oncorus | Celgene investment in Series B - Oncorus | 79.5 M USD |
| 2019-08-06 | Cleave Therapeutics | Celgene investment in Series C - Cleave Therapeutics | 12 M USD |
| 2019-07-09 | GNS Healthcare | Celgene investment in Series D - GNS Healthcare | 23 M USD |
| 2019-04-30 | Vividion Therapeutics | Celgene investment in Series B - Vividion Therapeutics | 82 M USD |
| 2019-04-18 | Arrakis Therapeutics | Celgene investment in Series B - Arrakis Therapeutics | 75 M USD |
| 2019-02-07 | HiberCell | Celgene investment in Series A - HiberCell | 60.75 M USD |
| 2019-01-08 | Biond Biologics | Celgene investment in Series B - Biond Biologics | 17 M USD |
Official Site Inspections
http://www.bms.com
- Host name: 45.60.170.161
- IP address: 45.60.170.161
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Celgene"
Global Biopharmaceutical Company - Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases.See details»
About us - Bristol Myers Squibb
We are a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. At Bristol Myers Squibb, we work every day to transform patients’ lives through science.See details»
Our leadership team - Bristol Myers Squibb
Meet the executive leaders at Bristol Myers Squibb who are not only responsible for day-to-day operations, but are also innovators in the biotech industry committed to patients, customers, employees, community and stockholders.See details»
Bristol Myers Squibb - Wikipedia
The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company.Headquartered in Princeton, New Jersey, [2] BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 …See details»
Org Chart Bristol-Myers Squibb - The Official Board
Download your org chart in Excel • Bristol-Myers Squibb org chart • Bristol-Myers Squibb org chart with its 23 subsidiaries (24 org charts) Print your org chart in PDF • Bristol-Myers Squibb org chartSee details»
Bristol-Myers Squibb - The Org
Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases.See details»
Annual Report 2023 - Bristol Myers Squibb
We are committed to discovering, developing and delivering transformational medicines in disease areas where we believe we can make a meaningful difference — and we made strong progress in 2023.See details»
Life At BMS - BMS Careers
At Bristol Myers Squibb, you’ll join a diverse, high-achieving team united by a common mission. You’ll grow and thrive through opportunities that are uncommon in scale and scope. You’ll pursue innovative ideas while advancing professionally alongside some of …See details»
Bristol Myers Squibb - LinkedIn
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience.See details»
Global Product Development and Supply - BMS Careers
Our Global Product Development and Supply (GPS) organization brings hope to our patients around the world through the sustainable development and delivery of high-quality, innovative and life-changing medicines. While our work transforms the lives of patients, it also transforms the lives and careers of those who do it.See details»
Global Inclusion & Diversity - Bristol Myers Squibb
At Bristol Myers Squibb, our global commitment to inclusion and diversity (GI&D) strengthens our ability to serve the evolving needs of patients and communities, our people, our business and industry. Our value of inclusion defines who we are and how we do business.See details»
Country | Canada - BMS Careers
In Canada, we have three People and Business Resource Groups (PBRGs) to support the business objectives, career advancement and development needs of our employees. These include a local chapter of the following groups: Bristol Myers Squibb Network of Women (B-NOW)See details»
Annual Report 2021 - Bristol Myers Squibb
Learn how a single touch can transform patients’ lives in Bristol Myers Squibb’s 2021 Annual Report.See details»
Bristol Myers Squibb - Bristol Myers Squibb Announces Progress …
Mar 15, 2023 · In 2020, Bristol Myers Squibb (BMS) and the Bristol Myers Squibb Foundation, an independent charitable organization, each committed $150 million over five years, totaling $300 million to address health equity efforts by 2025.See details»
Bristol Myers Squibb - Bristol Myers Squibb to Participate in Citi’s ...
2 days ago · Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in Citi’s 2024 Global Healthcare Conference. Christopher Boerner, Ph.D., board chair and chief executive officer, will take part in a fireside chat on December 3, 2024. He will answer questions about the company beginning at 8:00 a.m. ET. Investors and the general public are …See details»
2023 ESG Report - Bristol Myers Squibb
Explore Bristol Myers Squibb's 2023 ESG Report to discover our commitment to environmental, social and governance practices. Learn about our progress, initiatives and future sustainability goals.See details»
People and business resource groups - Bristol Myers Squibb
Learn more about the leaders of the company’s People & Business Resource Groups (PBRGs), who report directly to members of our Leadership Team and act as an advisory group on key business initiatives related to diversity and inclusion efforts.See details»
Press Releases - Bristol Myers Squibb
Media Inquiries: [email protected]. Investor Relations: [email protected]. Subscribe to our RSS feed. Receive updated news from preferred websites, which are sent directly to the user's news reader. This includes the headlines, summaries and links to …See details»
Nivolumab in Patients With Advanced or Metastatic Malignancies ...
1 day ago · PURPOSETo report on CheckMate 627 (ClinicalTrials.gov identifier: NCT02832167), a phase II adaptive basket design trial of nivolumab in uncommon advanced/metastatic tumors.METHODSAdults with previously treated advanced/metastatic malignancies received ...See details»
Corporate governance and management - Bristol Myers Squibb
Find out about Bristol Myers Squibb's corporate governance, ensuring the company operates in the most reliable, efficient, transparent and ethical manner.See details»